Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
953results about How to "Inhibit progress" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of disease
InactiveUS20060167498A1Reduce or prevent conditionReducing and preventing symptomSpinal electrodesSurgical needlesSplanchnic nervesDisease
The present invention teaches a method and apparatus for physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, depression, epilepsy, and diabetes. This includes chronically implanted neural and neuromuscular modulators, used to modulate the afferent neurons of the sympathetic nervous system to induce satiety. Furthermore, this includes neuromuscular stimulation of the stomach to effect baseline and intermittent smooth muscle contraction to increase gastric intraluminal pressure, which induces satiety, and stimulate sympathetic afferent fibers, including those in the sympathetic trunk, splanchnic nerves, and greater curvature of the stomach, to augment the perception of satiety.
Owner:DILORENZO BIOMEDICAL
FcgammaRIIB-specific antibodies and methods of use thereof
ActiveUS20040185045A1Strong therapeutic activityEnhancing antibody-mediated effector functionSenses disorderAntipyreticTherapeutic antibodyTreatment effect
The present invention relates to antibodies or fragments thereof that specifically bind FcgammaRIIB, particularly human FcgammaRIIB, with greater affinity than said antibodies or fragments thereof bind FcgammaRIIA, particularly human FcgammaRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
Owner:MACROGENICS INC
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
ActiveUS8252592B2Increase self-toleranceIncrease and reduces immune responseFused cellsFermentationRegulatory T cellLymphocyte
Owner:MEMORIAL SLOAN KETTERING CANCER CENT
External wearable light therapy treatment systems
InactiveUS20070129776A1Reinforced jointsImprove abilitiesDiagnosticsSurgeryLight therapyLight energy
A light therapy system provides for self-alignment or positioning with respect to a joint of a subject. The light therapy system can provide light therapy to a body part of a subject. The therapy system has a main body configured to be placed adjacent a target site and an activatable light emitting system is coupled to the main body. The light emitting system is capable of delivering a therapeutic amount of light energy to the target site when the main body is placed adjacent the target site.
Owner:LIGHT SCI ONCOLOGY
2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4)
![2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones](https://images-eureka.patsnap.com/patent_img/211494ac-0ef3-4b13-a9b2-61f9ab91cee8/US06936612-20050830-C00001.png "2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones")
![2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones](https://images-eureka.patsnap.com/patent_img/211494ac-0ef3-4b13-a9b2-61f9ab91cee8/US06936612-20050830-C00002.png "2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones")
![2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones](https://images-eureka.patsnap.com/patent_img/211494ac-0ef3-4b13-a9b2-61f9ab91cee8/US06936612-20050830-C00003.png "2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones")
Owner:WARNER LAMBERT CO LLC
Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
Adipose derived regenerative cells are used to treat patients, including patients with cardiovascular conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells, e.g., stem and / or progenitor cells, obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, adipose derived regenerative cells are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic cardiovascular benefit.
Owner:LOREM VASCULAR PTE LTD
Method and apparatus for conformal electrodes for autonomic neuromodulation for the treatment of obesity and other conditions
InactiveUS20090118780A1Reduce or prevent conditionReducing and preventing symptomSpinal electrodesHead electrodesAfferent NeuronsAutonomic Denervation
The present invention teaches a method and apparatus for user control and operation of physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, metabolic disease, and other conditions. This includes programming of neuromodulatory signal for the modulation of autonomic neural and neuromuscular modulators, used to modulate tissues, including the afferent neurons of the sympathetic nervous system to induce satiety and efferent neurons to modulate metabolism. The apparatus and methods include a conformal neuromodulator array which facilitates minimally invasive placement of neuromodulators in communication with target tissues.
Owner:DILORENZO DANIEL JOHN
Systems for Sustained Intraocular Delivery of Low Solubility Compounds from a Port Delivery System Implant
ActiveUS20140276482A1Improve solubilityHigh concentrationOrganic active ingredientsPharmaceutical delivery mechanismSolubilityBiomedical engineering
Therapeutic agent delivery formulations for the sustained release of therapeutic agents from a Port Delivery System (PDS) implant is described in this application.
Owner:FORSIGHT VISION5 INC
Methods of treating metabolic syndrome using dopamine receptor agonists
InactiveUS20080200453A1Relieve symptomsEffective treatmentBiocideMetabolism disorderDiseaseVascular disease
The present invention is directed to a method of simultaneously treating hypertension, hypertriglyceridemia, a pro-inflammatory state, a pro-coagulative state, and insulin resistance (with or without treating obesity or endothelial dysfunction), associated with or independent from Metabolic Syndrome, as well as vascular disease such as cardiovascular, cerebrovascular, or peripheral vascular disease comprising the step of administering to a patient suffering from such disorders a therapeutically effective amount of a central acting dopamine agonist. In one embodiment, the central acting dopamine agonist is bromocriptine, optionally combined with a pharmaceutically acceptable carrier.
Owner:VEROSCI
Contact lens comprising non-coaxial lenslets for preventing and/or slowing myopia progression
ActiveUS20160377884A1Good distance vision correctionCorrection acuitySpectales/gogglesOptical partsPupilRetina
Contact lenses incorporating an array of non-coaxial lenslets with add power that create non-coaxial myopic defocus within the optic zone of the lens may be utilized to prevent and / or slow myopia progression. The positive, non-coaxial lenslets cover about twenty to eighty percent of the central pupil area to deliver positive foci of light in front of the retina to slow the rate of myopia progression.
Owner:JOHNSON & JOHNSON VISION CARE INC
Method and apparatus for programming of autonomic neuromodulation for the treatment of obesity
InactiveUS20090187230A1Reduce or prevent conditionReducing and preventing symptomSensorsDigestive electrodesAfferent NeuronsDisease
The present invention teaches methods and apparatus for user control and operation of physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity. This includes programming of neuromodulatory signal for the modulation of autonomic neural and neuromuscular modulators, used to modulate tissues, including the afferent neurons of the sympathetic nervous system to induce satiety and efferent neurons to modulate metabolism.
Owner:DILORENZO DANIEL J
Compounds and methods for treatment of cancer
ActiveUS20070004627A1Reduce tumor volumeInhibit tumor growthBiocidePeptide/protein ingredientsLymphatic SpreadImproved survival
The invention relates to methods and compounds for treating or preventing cancer. Methods for treating or preventing cancer, for inhibiting tumor growth, reducing tumor volume, inhibiting tumor progression, inhibiting metastasis, and improving survival are provided herein.
Owner:FIBROGEN INC
Gsk-3betainhibitor
InactiveUS20100069381A1Superior GSK-3 specific inhibitory activityImprove solubilityAntibacterial agentsBiocideDiseaseDitazole
For the purpose of providing a GSK-3β inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (I):wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.
Owner:TAKEDA PHARMA CO LTD
Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
ActiveUS20100178276A1Prevent metastasisPrevent occurrence and recurrenceAntibacterial agentsAntimycoticsT cellT lymphocyte
The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT
Influenza virus vaccines and uses thereof
ActiveUS20100297174A1Reduce severityImprove survivalSsRNA viruses negative-sensePeptide/protein ingredientsHemagglutininInfluenza virus vaccine
Owner:MT SINAI SCHOOL OF MEDICINE
Antibody to cytokine response gene 2(CR2) polypeptide
InactiveUS6057427AHigh incidenceEliminate the effects ofCytokine-induced proteinsPeptide/protein ingredientsAntibody fragmentsAmino acid
PCT No. PCT / US96 / 08992 Sec. 371 Date Jun. 5, 1996 Sec. 102(e) Date Jun. 5, 1996 PCT Filed Jun. 5, 1996Disclosed are an isolated antibody or antibody fragment that selectively binds a polypeptide encoded by Cytokine Response gene 2 (CR2), and in particular, selectively binds to a first polypeptide having the sequence of residues 1-60 of SEQ. ID No: 4. Also disclosed is a composition containing the antibody or antibody fragment and a diluent or carrier. Also disclosed are methods, using the present antibody or antibody fragment, of isolating or purifying a peptide comprising an amino acid sequence of residues 1-60 of SEQ. ID No: 4 or an antibody binding fragment thereof that is at least 10 to 30 amino acids long, or a fusion protein comprising any of these.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders
InactiveUS20090269356A1Lower Level RequirementsImprove acuityBiocideSenses disorderDiseaseEye disease
Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject's complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-complement aptamer that, in a preferred embodiment, is an anti-C5 aptamer.
Owner:ARCHEMIX CORP
Immunoglobulin variants and uses thereof
InactiveUS20100098730A1Preventing occurrencePrevent recurrenceImmunoglobulins against growth factorsAntibody ingredientsHalf-lifeIn vivo
Variant immunoglobulins with one or more amino acid modifications in the Fc region that have increased in vivo half-lives, and methods of using the same are provided.
Owner:F HOFFMANN LA ROCHE & CO AG
Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
InactiveUS20060257451A1Inhibit progressQuantity maximizationSenses disorderEye implantsChoroid membraneOphthalmology
The invention relates to sustained release implants and to methods for treating eyes, particularly the eyes of mammals having eye disorders or diseases. By using the implants and methods described herein, the delivery of the one or more bioactive agents can be localized at a desired treatment site, particularly the choroid and the retina.
Owner:SURMODICS INC
Effective generation of tumor-targeted t cells derived from pluripotent stem cells
ActiveUS20160009813A1Improve survivalGood antitumor activityAntibody mimetics/scaffoldsMammal material medical ingredientsAntigenPluripotential stem cell
The present invention relates to the field of adoptive immunotherapy. The invention provides methods for generating phenotypically defined, functional, and / or expandable T cells from pluripotent stem cells engineered through safe genetic modifications. The engineered cells may provide one or more of: 1) targeting a specific predetermined antigen expressed on the cell surface of a target cell in an HLA independent manner, 2) enhanced survival and functional potential 3) “off-the-shelf” T cells for administration to multiple recipients, eventually across immunogenic barriers, and / or 4) cytotoxic potential and anti-tumor activity.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT
Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d] pryimidin-7-ones
InactiveUS7781583B2Inhibit progressUtility as antiinfective agentsOrganic chemistryAntineoplastic agentsStereochemistry
The present invention provides methods of preparing substituted 2-(pyridin-2-ylamino)-pirido[2,3-d]pyrimidin-7-ones (formula 1),useful in treating cell proliferative disorders, or a pharmaceutically acceptable salt thereof.
![Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d] pryimidin-7-ones](https://images-eureka.patsnap.com/patent_img/b5389c6e-f65c-4c14-baec-46f878c60f3e/US07781583-20100824-C00001.png "Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d] pryimidin-7-ones")
![Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d] pryimidin-7-ones](https://images-eureka.patsnap.com/patent_img/b5389c6e-f65c-4c14-baec-46f878c60f3e/US07781583-20100824-C00002.png "Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d] pryimidin-7-ones")
![Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d] pryimidin-7-ones](https://images-eureka.patsnap.com/patent_img/b5389c6e-f65c-4c14-baec-46f878c60f3e/US07781583-20100824-C00003.png "Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d] pryimidin-7-ones")
Owner:PFIZER INC
Artificial cornea
An artificial cornea comprising an optical element made of an optically transparent material, having a front surface and a posterior surface, and a skirt provided so as to support with surrounding at least a part of the optical element, characterized in that the skirt is provided with a flange on its side facing the interior of eyes during implantation of the artificial cornea and the flange radially protrudes outward from the skirt. The artificial cornea can be well compatible with ocular tissue, prevent leakage of intraocular aqueous humor and intraocular invasion of bacteria, reduce stimulation on palpebral conjunctiva and further, inhibit progression of the down growth, and which has no possibility of reduction in transparency of the optical element due to the down growth as well as detachment and extrusion from the implanted state.
Owner:MENICON CO LTD
Treatment of disc degenerative disease and compositions for same
ActiveUS20100008992A1Improve angiogenesisInhibit progressBiocidePowder deliveryCell typeLBP - low back pain
Methods and compositions for treating or ameliorating lower back pain by administering an effective amount of one or more cell types, alone, and / or in combination with a matrix, and / or in combination with growth factors, in order to stimulate lumbar angiogenesis, decrease inflammation, and stimulating regeneration.
Owner:STEMSPINE INC
Human regulatory molecules
The invention provides human regulatory molecules and polynucleotides (collectively designated HRM) which identify and encode them. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing, preventing, and treating disorders associated with expression of human regulatory molecules.
Owner:INCYTE PHARMA INC
Compositions and methods for modulating NH2-terminal Jun Kinase activity
InactiveUS7232897B2Reduce expressionIncrease insulin sensitivityOrganic active ingredientsBiocideDiabetes mellitusKinase
Disclosed herein are compositions and methods used to modulate a NH2-terminal Jun Kinase activity. These compositions and methods can be employed to regulate metabolic disorders associated with, for example, insulin such as diabetes. The reduction in NH2-terminal Jun Kinase activity can lead to the reduction in weight and improve insulin sensitivity.
Owner:HARVARD UNIV
Extracellular adhesive proteins
InactiveUS20010010913A1High viscosityHighly concentrated solutionAntibacterial agentsFungiExtracellularAgonist
The invention provides human extracellular adhesive proteins (EXADH) and polynucleotides which identify and encode EXADH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of EXADH.
Owner:INCYTE PHARMA INC
Methods, systems, and kits for plaque stabilization
InactiveUS20030069525A1Increasing the thicknessHigh strengthUltrasound therapySurgeryBlood vessel wallsGrowth Factor Gene
Atherosclerotic plaque and blood vessels may be stabilized by directing vibrational energy, typically ultrasonic energy, into the adjacent blood vessel wall. Application of the vibrational energy, optionally in combination with growth factors, growth factor genes, or other substances which enhance growth stability of a fibrotic cap over the plaque, will reduce the risk of rupture of unstable plaque and inhibit the conversion of stable plaque into unstable plaque.
Owner:PHARMASONICS
Method of cutting semiconductor wafer and protective sheet used in the cutting method
InactiveUS7060531B2Suppressing progressInhibit progressFilm/foil adhesivesSemiconductor/solid-state device detailsForming faceResist
In a method of cutting a semiconductor wafer in which the semiconductor wafer 6 is cut by plasma etching, a protective sheet 30 on which a metallic layer 30b, a plasma etching rate of which is low, is formed on one face of an insulating sheet 30a is stuck on to a circuit forming face 6a by an adhesive layer 30c, and plasma is exposed onto an opposite side to the circuit forming face 6a from a mask side which is formed by covering regions except for cutting lines 31b with a resist film 31a so as to conduct plasma etching on portions of the cutting lines. Due to the above structure, it is possible to use the metallic layer as an etching stop layer for suppressing the progress of etching. Therefore, fluctuation of the progress of etching can be avoided and heat damage caused on the protective sheet can be prevented.
Owner:PANASONIC CORP
Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
ActiveUS20100092978A1Inhibit expressionInhibit progressSugar derivativesMicrobiological testing/measurementCancer preventionBacteriuria
Compositions and methods for diagnosing, treating and / or preventing cancers characterized by CDH17 overexpression based on the detection of CDH17 or the use of CDH17 as a target for therapeutic intervention or prophylactic intervention are provided. Methods for diagnosing and / or monitoring liver cancers using the expressing of CDH17 involve detecting and / or quantitating the CDH17 protein or encoding nucleic acids (DNA or RNA) in a biological sample such as urine from the subject. Methods for treating liver cancers using CDH17 as a target and of sensitizing cells with aberrant expression of CDH17 have also been developed. The methods include suppression or knockdown of the expression of CDH17 by administering an effective amount of a CDH17 inhibitor.
Owner:THE UNIVERSITY OF HONG KONG
Methods of modulating immune function
ActiveUS20120219559A1Modulate its functionAdjust immune functionBiocidePeptide/protein ingredientsCTLA-4Autoimmune disease
Presented herein are therapeutic agents that modulate one or more immune functions and uses of such therapeutic agents in the prevention, treatment and management of diseases. In one aspect, the therapeutic agents modulate one or more signal transduction pathways induced by the binding of B7-H7 to B7-H7CR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. In another aspect, the therapeutic agents modulate the binding of B7-H7 to B7-H7CR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. The therapeutic agents can be used in the prevention, treatment and / or management of diseases in which it might be useful to modulate one or more immune functions (e.g., cancer, infectious disease, autoimmune disease, and transplantation rejection). In another aspect, presented herein are methods for identifying receptor-ligand interactions.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com